Provident Co of the Employees of the Hebrew University LTD Lowers Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Provident Co of the Employees of the Hebrew University LTD lessened its stake in Moderna, Inc. (NASDAQ:MRNA) by 20.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,113 shares of the company’s stock after selling 4,097 shares during the period. Moderna makes up about 0.8% of Provident Co of the Employees of the Hebrew University LTD’s holdings, making the stock its 27th biggest holding. Provident Co of the Employees of the Hebrew University LTD’s holdings in Moderna were worth $669,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. State Street Corp raised its holdings in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after buying an additional 1,823,276 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Moderna by 21.0% during the third quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock worth $349,166,000 after acquiring an additional 906,114 shares in the last quarter. Amundi lifted its holdings in shares of Moderna by 79.8% in the 4th quarter. Amundi now owns 1,206,273 shares of the company’s stock worth $52,075,000 after acquiring an additional 535,273 shares during the last quarter. Two Sigma Advisers LP bought a new stake in shares of Moderna in the 3rd quarter worth approximately $23,825,000. Finally, Douglas Lane & Associates LLC boosted its stake in shares of Moderna by 62.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 773,804 shares of the company’s stock valued at $32,175,000 after purchasing an additional 298,715 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MRNA. Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Berenberg Bank boosted their target price on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Royal Bank of Canada restated a “sector perform” rating and set a $40.00 target price on shares of Moderna in a report on Tuesday, February 18th. Evercore ISI set a $50.00 price target on Moderna in a research note on Friday, February 14th. Finally, HSBC raised Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research note on Monday, November 18th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $59.60.

Moderna Trading Up 0.9 %

MRNA opened at $34.62 on Monday. The company has a market cap of $13.36 billion, a price-to-earnings ratio of -3.73 and a beta of 1.86. The stock has a fifty day simple moving average of $35.94 and a two-hundred day simple moving average of $47.15. Moderna, Inc. has a 12-month low of $29.25 and a 12-month high of $170.47.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.